CAR T-cell therapy (CD19-targeted)

CD19-targeted chimeric antigen receptor (CAR) T-cell therapy is a class of cellular immunotherapies designed to target and eliminate B cells expressing the CD19 antigen. This therapy involves harvesting a patient's (or donor's) T cells, genetically engineering them ex vivo to express a CAR specific to CD19, expanding them, and reinfusing them into the patient. CD19 is a transmembrane glycoprotein widely expressed across B-cell development stages and on most B-cell malignancies, making it a highly effective target for hematologic cancers. Several CD19-targeted CAR T-cell therapies have been approved by regulatory agencies, including tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), and lisocabtagene maraleucel (Breyanzi), primarily for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and other B-cell lymphomas. Additionally, CD19 CAR-T therapies are being actively investigated for severe autoimmune diseases such as systemic lupus erythematosus (SLE) and systemic sclerosis.

Other names

CD19 CAR-TCD-19 CAR-TCD 19 CAR-TCD19 CAR-T cell therapyCD-19 CAR-T cell therapyCD 19 CAR-T cell therapyCD19-targeted CAR T-cell therapyCD-19-targeted CAR T-cell therapyCD 19-targeted CAR T-cell therapyCD19-targeted chimeric antigen receptor T-cell therapyCD-19-targeted chimeric antigen receptor T-cell therapyCD 19-targeted chimeric antigen receptor T-cell therapyanti-CD19 CAR-Tanti-CD-19 CAR-Tanti-CD 19 CAR-Tanti-CD19 CAR-T cell therapyanti-CD-19 CAR-T cell therapyanti-CD 19 CAR-T cell therapyanti-CD19 chimeric antigen receptor T-cell therapyanti-CD-19 chimeric antigen receptor T-cell therapyanti-CD 19 chimeric antigen receptor T-cell therapychimeric antigen receptor T-cell therapy (CD19-targeted)